Long Term Estrogen Loss Worsens Heart Function in Aged Female Mice
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METHODOLOGY

ABSTRACT

INTRODUCTION
Cardiovascular Disease is responsible
for 17.7 million deaths in the world, and
655,000 in the United States alone according
to the Center of Disease Control. Risk factors
such as high blood pressure, high cholesterol,
age and sex hormones (estrogen deficiency)
can increase the risk of heart disease. A
common feature of cardiac failure is increased
chronic beta-adrenergic stimulation.
Chronic sympathetic stimulation results
in disturbed homeostasis, heart failure and
increased contractility of the cardiomyocyte.
Systolic dysfunction occurs as a result from
mitochondrial dysfunction, cardiac remodeling
inflammation, ventricular hypertrophy, and
impaired G protein-coupled receptors.
This result is due to the stimulation of
beta-adrenergic receptors (β-AR’s), part of the
G-coupled receptors. Both clinical and animal
studies show that estrogen loss and age
exacerbate cardiac β-AR signaling and
contractile function is mediated by G proteincoupled
receptor
kinases
(GPRK2).
Dysfunction in myocardial β-AR dysregulate
the contractility of AC-PKA pathway activation,
increased epinephrine and norepinephrine.
Cardiac sympathetic stimulation via heart
failure contractility is increased due to GRK2
phosphorylating β-AR’s and regulating ACPKA.
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Figure 1: Timeline of Experimental Methods:
A) 5M models were infused with saline or ISO at
7.5 months for 3 days. The B) 12M models were
infused with saline or ISO at 14.5 months for 3
days.
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i. Bilateral ovariectomy (OVX) or SHAM
surgery was performed in female mice at
2.5 months of age.
ii. Mice were infused with Isoproterenol
(ISO; 400μg/kg/h) at 5 months (5M) post
OVX for 3 days or 12 months (12M) post
OVX for 3 days via mini osmotic pumps to
induce chronic sympathetic stimulation.
SHAM and OVX groups were treated with
saline.
iii. Transthoracic M-Mode echocardiography
was used to observe cardiac function in
the form of fractional shortening (%FS)
and ejection fraction (EF).
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Figure 2A-D: 12M echocardiography M-Mode
tracings of left-ventricular diastolic and
systolic diameter for A) SHAM, B) OVX, C) ISO,
and D) ISO +OVX treatment groups.
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Understanding the effects of estrogen loss
and HD is crucial to improving and
finding alternative treatments for aging
menopausal women. with heart disease.
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i. OVX,ISO, and ISO+OVX significantly
decreased in S-Diameter in 5M and 12M.
ii. Largest decrease in S-Diameter was in
ISO+OVX group for 5M and 12M. 12M had
a greater decrease in S-Diameter than 5M.
iii. SHAM compared to SHAM +ISO
decreased in D-Diameter at only at 12M.
D-Diameter
significantly
decreased
between 5M and 12M.
Ovariectomy
(prolonged
estrogen
deficiency):
i. OVX group increased %FS and EF
between 5M and 12M time models.
ii. SHAM compared to OVX group
increased %FS and EF within groups at
5M and 12M models.
iii. SHAM compared to OVX had higher
%FS and EF at 12M.
Isoproterenol
(Chronic
Sympathetic
Stimulation):
i. SHAM +ISO compared to ISO+OVX
group increased %FS and EF within
groups in the 5M and 12M models.
ii. SHAM compared to SHAM+ISO group
resulted in a 1.2-fold increase of %FS
and EF in the 5M model.
iii. SHAM and SHAM+ISO compared to the
OVX+ISO group resulted in a greater fold
increase in %FS and EF in the 12M
model than the 5M.
iv. OVX compared to OVX+ISO group
resulted in a 1.8-fold increase of %FS
and EF at 5M.
CONCLUSIONS
The results presented here show that
estrogen loss impairs left ventricular cardiac
response to β-AR stimulation, and that
prolonged estrogen loss may blunt the
sympathetic response in the heart. These
results highlight the importance of studying the
long-term effects of estrogen loss during
menopause in the treatment and management
of heart disease.
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To mimic menopause, we surgically removed
the ovaries from female mice at 2.5 months
of age, waited 5 or 12 months for estrogen
loss, and induced heart failure using a drug
that increases the contractility of the heart.
Our results show that estrogen loss at 12
months caused a greater impairment
on the heart’s response in increased heart
contractility.
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Our hypothesis is that long-term
estrogen loss following heart failure
worsens cardiac function of the aged
female heart.

Table 1: 5-and 12-Month Mice Treatment
Groups: The four treatment groups include
SHAM, OVX, ISO and OVX+ISO (n=5, n=5,
n=7, and n=5, respectively).
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Heart disease is the leading cause
of death worldwide and according to
the American Heart Association, the risk
of HD in aging menopausal women
doubles compared to men of the same
age. Excessive contractility of blood vessels
is a common feature in heart disease.
Clinical and animal studies further support
that estrogen loss worsen the contractility
in the heart but the details remain unclear.
Thus, the overall goal of this work was to
examine how the timing and duration
of estrogen loss affects heart failure.
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Figure 2: Echocardiographic calculations of left ventricular structure and function A) Systolic diameter B) Diastolic
Diameter C) Fractional Shortening D) Ejection Fraction. Statistical analysis was performed using student t-test, n=5-7;
#P<0.05 vs. 5-MOS OVX;
*P<0.001 vs. 5-MOS-SHAM+ISO, &P<0.05 vs SHAM+ISO within time group, @P<0.05 vs. OVX within time group,
$P<0.05 vs. ISO+OVX within time group, %P<0.05 vs. ISO+OVX within time group
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